Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy

Transplant International

Volumn 22, Issue 5, 2009, Pages 586-587

  Neau Cransac, Martine ^a   Moreau, Karine ^a   Deminière, Colette ^a   Merville, Pierre ^a   Saric, Jean ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CANDESARTAN HEXETIL; CORTICOSTEROID; EVEROLIMUS; INSULIN; NICARDIPINE; PRAVASTATIN; RAPAMYCIN; TACROLIMUS;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANEMIA; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; HUMAN; LETTER; LIVER TRANSPLANTATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT;

CARCINOMA, SQUAMOUS CELL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; SIROLIMUS;

EID: 64249162468     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00811.x     Document Type: Letter

References (12)

1. Kreis H, Oberbauer R, Campistol JM, et al. Rapamune maintenance regimen trial. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004 15 : 809.
2. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007 84 : 467.
3. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006 21 : 488.
4. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007 2 : 326.
5. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Neprol Dial Transplant 2006 21 : 3252.
6. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005 80 : 1198.
7. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immuno-suppression in long-term cardiac transplant patients. Am J Transplant 2008 8 : 1.
8. Dervaux T, Caillard S, Meyer B, et al. Is sirolimus responsible for proteinuria Transplant Proc 2005 37 : 2828.
9. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005 80 : 244.
10. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008 27 : 141.
11. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006 12 : 1640.
12. De Simone P, Petruccelli S, Precisi A, et al. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient-not all proliferation signal inhibitors are the same: a case report. Transplant Proc 2007 39 : 3500.